Supplemental Table 1. Frequency distribution of selected characteristics in neuroblastoma patients and cancer-free controls

Variables	Guangdong province					Henan province				
	Cases (N=256)		Controls (N=531)		P [a]	Cases (N=118)		Controls (N=281)		P [a]
	No.	%	No.	%		No.	%	No.	%	
Age range, month	0-156		0.07-156		0.239	0-131.1		0.1-144.0		0.189
Mean ± SD	30.87 ± 26.45		29.73 ± 24.86			46.24 ± 29.98		44.97 ± 33.23		
≤18	101	39.45	233	43.88		23	19.49	72	25.62	
>18	155	60.55	298	56.12		95	80.51	209	74.38	
Gender					0.333					0.196
Female	103	40.23	233	43.88		54	45.76	109	38.79	
Male	153	59.77	298	56.12		64	54.24	172	61.21	
Clinical stages										
I	54	21.09				15	12.71			
II	65	25.39				31	26.27			
III	44	17.19				19	16.10			
IV	77	30.08				49	41.53			
4s	9	3.52				3	2.54			
NA	7	2.73				1	0.85			
Sites of origin										
Adrenal gland	46	17.97				89	75.42			
Retroperitoneal region	87	33.98				/	/			
Mediastinum	90	35.16				19	16.10			
Other region	25	9.77				10	8.47			
NA	8	3.13				/	/			

SD, standard deviation; NA, not available.

[a] Two-sided χ^2 test for distributions between neuroblastoma patients and cancer-free controls.

Supplemental Table 2. SNPs captured by the five selected *LMO1* polymorphisms as predicted by SNPinfo (http://snpinfo.niehs.nih.gov/) software

rs	Chr	Allele	LDsnp	Pop/R^2	TFBS	Splicing (ESE or ESS)	Reg Potential	Conservation[a]	Nearby Gene	Distance (bp)	Allele	Asian	CHB
rs1042359	**11**	**G/A**	**rs1042359**	**1**	**--**	**--**	**0.460373**	**1**	**LMO1**	**324||39225**	**A**	**0.921**	**0.923**
rs4758053	11	C/T	rs1042359	CHB/0.650	--	--	0.290163	0.002	LMO1	3885||35664	C	0.943	0.952
rs6578942	11	C/T	rs1042359	CHB/0.757	--	--	0.228962	0	RIC3||LMO1	-52598||-2687	C	0.947	0.927
rs7109806	11	C/T	rs1042359	CHB/0.757	--	--	0.035911	0.001	RIC3||LMO1	-52057||-3228	T	0.939	0.929
rs7122225	11	A/G	rs1042359	CHB/0.611	--	--	0.142751	0.002	RIC3||LMO1	-49246||-6039	G	0.960	0.929
rs767838	11	G/T	rs1042359	CHB/0.741	--	--	0.331973	0.004	RIC3||LMO1	-53176||-2109	G	0.936	0.911
rs7933956	11	C/T	rs1042359	CHB/0.675	--	--	0.092952	0	LMO1	1274||38275	C	0.939	0.946
rs11041838	**11**	**C/G**	**rs11041838**	**1**	**Y**	**--**	**0.013866**	**0.002**	**LMO1||STK33**	**-3681||-124331**	**G**	**0.500**	**0.875**
rs2071458	**11**	**C/A**	**rs2071458**	**1**	**Y**	**--**	**0.333636**	**1**	**LMO1**	**39267||282**	**C**	**0.756**	**0.774**
rs2168101	**11**	**C/A**	**rs2168101**	**1**	**--**	**--**	**0.316134**	**1**	**LMO1**	**9551||29998**	**C**	**--**	**--**
rs110419	11	A/G	rs3750952	CHB/0.780	--	--	0	0	LMO1	6996||32553	A	0.634	0.530
rs110420	11	C/T	rs3750952	CHB/0.827	--	--	0	0	LMO1	7192||32357	T	0.491	0.545
rs204926	11	G/A	rs3750952	CHB/0.948	--	--	0	0	LMO1	9249||30300	G	0.640	0.628
rs204928	11	G/A	rs3750952	CHB/0.786	--	--	0	0.001	LMO1	8576||30973	A	0.614	0.568
rs3750952	**11**	**G/C**	**rs3750952**	**1**	**--**	**Y**	**0.524312**	**1**	**LMO1**	**6064||33485**	**G**	**0.632**	**0.614**
rs4758317	11	A/C	rs3750952	CHB/0.819	--	--	0	0	LMO1	4954||34595	A	0.394	0.464

SNP, single nucleotide polymorphism; LD, linkage disequilibrium; TFBS, transcription factor binding sites; ESE, exon splicing enhancer; ESS, exon splicing silencer; CHB, Han Chinese in Beijing, China.

[a] Conservation score (17 Species) downloaded from UCSC genome bioinformatics web site (http://genome.ucsc.edu/).

Supplemental Table 3. Stratification analysis for the association between *LMO1* gene polymorphisms and neuroblastoma susceptibility (Southern Chinese subjects)

Variables	rs2168101 G>T				rs3750952 G>C				Protective genotypes [a]			
	GG	GT/TT	Adjusted OR [b]	P [b]	GG	GC/CC	Adjusted OR [b]	P [b]	0-1	2-5	Adjusted OR [b]	P [b]
	(Cases/Controls)		(95% CI)		(Cases/Controls)		(95% CI)		(Cases/Controls)		(95% CI)	
Age, month												
≤18	62/128	39/105	0.76 (0.47-1.22)	0.256	51/122	50/111	1.07 (0.67-1.71)	0.779	45/99	56/134	0.92 (0.58-1.47)	0.730
>18	104/147	50/151	**0.47 (0.31-0.70)**	**0.0002**	96/131	58/167	**0.48 (0.32-0.71)**	**0.0003**	84/119	70/179	**0.55 (0.37-0.82)**	**0.003**
Gender												
Females	69/126	34/107	**0.58 (0.36-0.94)**	**0.026**	57/116	46/117	0.80 (0.50-1.27)	0.342	51/98	52/135	0.74 (0.47-1.18)	0.209
Males	97/149	55/149	**0.57 (0.38-0.85)**	**0.006**	90/137	62/101	**0.59 (0.40-0.87)**	**0.008**	78/120	74/178	**0.64 (0.43-0.95)**	**0.026**
Sites of origin												
Adrenal gland	35/275	10/256	**0.30 (0.15-0.62)**	**0.001**	30/253	15/278	**0.44 (0.23-0.85)**	**0.014**	24/218	21/313	0.60 (0.33-1.11)	0.106
Retroperitoneal	53/275	34/256	0.68 (0.43-1.09)	0.109	43/253	44/278	0.92 (0.59-1.45)	0.729	38/218	49/313	0.90 (0.57-1.42)	0.645
Mediastinum	60/275	30/256	**0.54 (0.34-0.87)**	**0.011**	57/253	33/278	**0.53 (0.34-0.84)**	**0.007**	55/218	35/313	**0.45 (0.28-0.70)**	**0.0005**
Others	16/275	9/256	0.61 (0.26-1.40)	0.243	14/253	11/278	0.73 (0.33-1.65)	0.454	10/218	15/313	1.06 (0.47-2.40)	0.897
Clinical stages												
I+II+4s	73/275	45/256	**0.66 (0.44-0.997)**	**0.048**	62/253	56/278	0.82 (0.55-1.23)	0.343	56/218	62/313	0.77 (0.52-1.15)	0.204
III+IV	81/275	40/256	**0.52 (0.34-0.78)**	**0.002**	74/253	47/278	**0.56 (0.37-0.84)**	**0.005**	62/218	59/313	**0.65 (0.44-0.98)**	**0.037**

OR, odds ratio; CI, confidence interval.

[a] Protective genotypes that reduced neuroblastoma risk were rs2168101 GT/TT, rs1042359 AG/GG, rs11041838 GG, rs2071458 CA/AA, and rs3750952 GC/CC.

[b] Adjusted for age and gender, omitting the corresponding stratification factor.

Supplemental Table 4. Stratification analysis for the association between *LMO1* gene polymorphisms and neuroblastoma susceptibility (Northern Chinese subjects)

Variables	rs2168101 G>T				rs3750952 G>C				Protective genotypes [a]			
	GG	GT/TT	Adjusted OR [b]	*P* [b]	GG	GC/CC	Adjusted OR [b]	*P* [b]	0-1	2-5	Adjusted OR [b]	*P* [b]
	(Cases/Controls)		(95% CI)		(Cases/Controls)		(95% CI)		(Cases/Controls)		(95% CI)	
Age, month												
≤18	15/30	8/42	0.38 (0.14-1.02)	0.056	13/24	10/48	0.40 (0.15-1.04)	0.060	13/19	10/53	**0.28 (0.11-0.75)**	**0.011**
>18	64/102	31/107	**0.44 (0.26-0.74)**	**0.002**	52/96	43/113	0.67 (0.41-1.10)	0.114	42/70	53/139	0.63 (0.38-1.04)	0.070
Gender												
Females	38/40	16/69	**0.25 (0.12-0.51)**	**0.0001**	31/36	23/73	**0.38 (0.19-0.74)**	**0.005**	30/29	24/80	**0.30 (0.15-0.59)**	**0.0005**
Males	41/92	23/80	0.66 (0.36-1.20)	0.171	34/84	30/88	0.89 (0.50-1.59)	0.691	25/60	39/112	0.88 (0.48-1.61)	0.680
Sites of origin												
Adrenal gland	60/132	29/149	**0.40 (0.24-0.67)**	**0.0005**	47/120	42/161	0.64 (0.39-1.03)	0.068	39/89	50/192	**0.59 (0.36-0.96)**	**0.032**
Mediastinum	14/132	5/149	**0.29 (0.10-0.83)**	**0.021**	14/120	5/161	**0.25 (0.09-0.71)**	**0.009**	12/89	7/192	**0.27 (0.10-0.70)**	**0.008**
Others	5/132	5/149	0.90 (0.25-3.23)	0.867	4/120	6/161	1.16 (0.31-4.30)	0.828	4/89	6/192	0.73 (0.20-2.68)	0.630
Clinical stages												
I+II+4s	31/132	16/149	**0.43 (0.22-0.82)**	**0.011**	28/120	19/161	**0.47 (0.25-0.89)**	**0.020**	25/89	22/192	**0.39 (0.21-0.74)**	**0.004**
III+IV	46/132	22/149	**0.40 (0.23-0.71)**	**0.002**	36/120	32/161	0.64 (0.37-1.10)	0.104	29/89	39/192	0.62 (0.36-1.07)	0.086

OR, odds ratio; CI, confidence interval.

[a] Protective genotypes that reduced neuroblastoma risk were rs2168101 GT/TT, rs1042359 AG/GG, rs11041838 GG, rs2071458 CA/AA, and rs3750952 GC/CC.

[b] Adjusted for age and gender, omitting the corresponding stratification factor.